FR05C0027I1 - - Google Patents

Info

Publication number
FR05C0027I1
FR05C0027I1 FR05C0027C FR05C0027I1 FR 05C0027 I1 FR05C0027 I1 FR 05C0027I1 FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 I1 FR05C0027 I1 FR 05C0027I1
Authority
FR
France
Prior art keywords
conopeptide
omega
medicament
manufacture
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed filed Critical
Publication of FR05C0027I1 publication Critical patent/FR05C0027I1/fr
Application granted granted Critical
Publication of FR05C0027I2 publication Critical patent/FR05C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
FR05C0027C 1995-06-27 2005-06-23 Active FR05C0027I2 (enrdf_load_stackoverflow)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (2)

Publication Number Publication Date
FR05C0027I1 true FR05C0027I1 (enrdf_load_stackoverflow) 2005-08-12
FR05C0027I2 FR05C0027I2 (enrdf_load_stackoverflow) 2006-12-29

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0027C Active FR05C0027I2 (enrdf_load_stackoverflow) 1995-06-27 2005-06-23

Country Status (13)

Country Link
EP (2) EP1336409B1 (enrdf_load_stackoverflow)
JP (1) JP2838073B2 (enrdf_load_stackoverflow)
AT (2) ATE235914T1 (enrdf_load_stackoverflow)
AU (1) AU695166B2 (enrdf_load_stackoverflow)
CA (1) CA2224795C (enrdf_load_stackoverflow)
DE (3) DE69637021T2 (enrdf_load_stackoverflow)
DK (2) DK0835126T3 (enrdf_load_stackoverflow)
ES (2) ES2194998T3 (enrdf_load_stackoverflow)
FR (1) FR05C0027I2 (enrdf_load_stackoverflow)
LU (1) LU91181I2 (enrdf_load_stackoverflow)
NL (1) NL300201I2 (enrdf_load_stackoverflow)
PT (2) PT835126E (enrdf_load_stackoverflow)
WO (1) WO1997001351A1 (enrdf_load_stackoverflow)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU6109698A (en) * 1998-02-20 1999-09-06 Zeneca Limited Analgesic peptides from venom of (grammostola spatulata) and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU2003302610B2 (en) 2002-12-02 2008-03-20 Xenome Ltd Novel chi-conotoxin peptides (-II)
AU2003302609B9 (en) 2002-12-02 2008-05-15 Xenome Ltd Novel chi-conotoxin peptides (-I)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2543350C2 (ru) 2003-01-28 2015-02-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
JP2010509209A (ja) * 2006-11-04 2010-03-25 エニジェン カンパニー リミテッド 新規なω−コノトキシン
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015003527A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de desordens associadas à retenção de fluido ou sobrecarga de sal e desordens do trato gastrointestinal
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
CA2224795A1 (en) 1997-01-16
DE122005000043I2 (de) 2006-08-03
PT835126E (pt) 2003-07-31
DK0835126T3 (da) 2003-07-14
DE69627153T2 (de) 2003-12-04
DE122005000043I1 (de) 2006-06-29
NL300201I1 (nl) 2005-09-01
EP1336409B1 (en) 2007-04-11
LU91181I2 (fr) 2005-09-06
JP2838073B2 (ja) 1998-12-16
ATE235914T1 (de) 2003-04-15
PT1336409E (pt) 2007-06-29
JPH09104634A (ja) 1997-04-22
CA2224795C (en) 2001-04-03
EP0835126A1 (en) 1998-04-15
DK1336409T3 (da) 2007-08-13
NL300201I2 (nl) 2006-02-01
DE69637021T2 (de) 2008-01-10
DE69627153D1 (de) 2003-05-08
HK1058146A1 (en) 2004-05-07
DE69637021D1 (de) 2007-05-24
ES2194998T3 (es) 2003-12-01
AU6400296A (en) 1997-01-30
WO1997001351A1 (en) 1997-01-16
EP1336409A1 (en) 2003-08-20
AU695166B2 (en) 1998-08-06
FR05C0027I2 (enrdf_load_stackoverflow) 2006-12-29
ATE359086T1 (de) 2007-05-15
ES2283671T3 (es) 2007-11-01
EP0835126B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
FR05C0027I2 (enrdf_load_stackoverflow)
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
ZA969520B (en) Use of epinastine for the treatment of pain
HUP9801777A3 (en) Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
IL121170A0 (en) Compositions for the treatment of dermatological disorders
GB2298440B (en) Well treatment
ZA9610139B (en) Treatment of the cns effects of hiv
AU7545594A (en) Implantable device for the treatment of aedemas
GB9512290D0 (en) Uses of polyhexanide
AU6328696A (en) Treatment of hemoglobinopathies
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU3105095A (en) Device for ensuring that medication is taken at the correct time
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
GB9303157D0 (en) Treatment of a group of related disorders
AP9200355A0 (en) "Therapeutic agent"
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
ZA9610433B (en) Medical use of proteases.
GB9419048D0 (en) Treatment of muscular disorders
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
ZA947912B (en) Treatment of medical disorders associated with free radical formation
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU5419894A (en) Dental treatment aid
GB9505681D0 (en) "Treatment"
GB9503143D0 (en) Treatment of depression